What is the history of Hyperparathyroidism?

Hyperparathyroidism was first clinically characterized in the early 20th century, evolving from a mysterious skeletal disorder to a condition now managed through precision endocrine surgery. Understanding of hyperparathyroidism shifted from viewing it as a rare bone-wasting disease to recognizing it as a common endocrine imbalance caused by overactive parathyroid glands.

When and how was hyperparathyroidism first identified?

The history of hyperparathyroidism is a testament to the power of clinical observation. In 1891, Friedrich Daniel von Recklinghausen described a condition involving bone deformity and cysts, later known as osteitis fibrosa cystica. It was not until 1925 that Austrian surgeon Felix Mandl performed the first successful parathyroidectomy on a patient with severe bone disease, definitively linking the overactive parathyroid glands to the skeletal symptoms of hyperparathyroidism. Before this breakthrough, physicians were often baffled by the rapid bone degeneration seen in patients, frequently misdiagnosing it as a primary bone cancer or nutritional deficiency.

How has the understanding of hyperparathyroidism evolved?

For decades, hyperparathyroidism was considered a rare, late-stage disease characterized by "stones, bones, abdominal groans, and psychic overtones." However, the introduction of automated serum calcium testing in the 1970s revolutionized our understanding of hyperparathyroidism. Physicians suddenly discovered that the disease was far more common than previously thought, often presenting in patients who were asymptomatic or had only mild, non-specific symptoms. This shift moved the diagnostic focus from advanced skeletal damage to early detection via biochemical screening.

What were the major milestones in the treatment of hyperparathyroidism?

The evolution of treatment has been defined by a move toward minimally invasive techniques. Key historical milestones include:

• 1925: Felix Mandl’s first successful surgical removal of a parathyroid adenoma.


• 1930s-1950s: The development of reliable laboratory assays to measure serum calcium and parathyroid hormone (PTH) levels.


• 1990s: The adoption of minimally invasive parathyroidectomy (MIP), which uses focused incisions guided by preoperative imaging.


• Modern Era: The use of intraoperative PTH monitoring, allowing surgeons to confirm the normalization of hormone levels in real-time before concluding the operation.

How have technology and genetics changed our perspective?

Modern genetics has clarified that while most cases of hyperparathyroidism are sporadic, a subset of patients carries hereditary syndromes such as Multiple Endocrine Neoplasia (MEN) types 1 and 2A. Genetic testing now allows families to identify at-risk members before symptoms manifest. Furthermore, advancements in nuclear medicine, such as Sestamibi scanning and 4D-CT imaging, have transformed the diagnostic landscape, allowing surgeons to locate the precise source of hyperparathyroidism with high accuracy before ever making an incision.

The role of patient advocacy in hyperparathyroidism

Historically, patients with hyperparathyroidism often struggled to be heard, as symptoms like fatigue or "brain fog" were frequently dismissed as psychological. Today, platforms like DiseaseMaps.org empower the 154 community members and others globally to share their lived experiences. This collective advocacy has shifted the clinical narrative, ensuring that patient-reported outcomes—not just blood test results—are prioritized in the management of hyperparathyroidism.

Next steps

• Consult an endocrine surgeon or an endocrinologist if you have persistent hypercalcemia.


• Review your historical lab results for trends in calcium and PTH levels.


• Join the 154 members on DiseaseMaps.org to connect with others sharing their experience with hyperparathyroidism.


• Ask your physician about genetic counseling if you have a strong family history of endocrine tumors.

Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD)


• Orphanet - The portal for rare diseases and orphan drugs


• Online Mendelian Inheritance in Man (OMIM) - Database of human genes and genetic disorders


• Journal of Clinical Endocrinology & Metabolism - Historical archives on parathyroid research